FierceBiotechFierceBioResearcherFierceVaccinesFiercePharma   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

Cell-based pandemic vaccine successful in human trial

  • Email
  • Print
  • Comment
  • Contact Author
  • Reprint

Baxter International says that a human trial of its Celvapan bird flu vaccine demonstrated that it spurred an immune response against three strains of the lethal virus. This is the first time that researchers have developed a flu vaccine using a virus grown in cell cultures rather than eggs. The new procedure is expected to be significantly faster and more efficient than the traditional manufacturing method. And that would be particularly important in the event a manufacturer was racing to produce large quantities of a vaccine to prevent a pandemic.

"It's not the complete answer to a possible pandemic, but it's one of many vaccines that look like they may be able to fight off a bird flu pandemic," said John Trenoar of the University of Rochester.

- here's Baxter's release
- read the story in the Chicago Tribune

Related Articles:
Baxter, GSK sign UK pandemic vaccine deal
WHO warns of rising bird flu pandemic risk

More stories about Vaccine   pandemic flu   bird flu   Celvapan   Baxter International  


Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.